Alnylam initiated with a Buy at EF Hutton

EF Hutton initiated coverage of Alnylam with a Buy rating and $304 price target. Alnylam’s journey from a venture-backed start-up attempting to transform RNA interference technology into a powerful new category of human therapeutics is "nothing short of remarkable," contends the firm, which adds that "perhaps more remarkable still is the compelling investment opportunity today at a $27 billion market cap."